出版國家:Scotland
出版周期:雙月刊
影響因子:2.067
研究領(lǐng)域:神經(jīng)病學(xué)、肽
5年影響因子:1.859
國外數(shù)據(jù)庫收錄:IM,2.067" />
醫(yī)學(xué)全在線
醫(yī)學(xué)全在線首頁-醫(yī)師-藥師-護士-衛(wèi)生資格-高級職稱-考試題庫-網(wǎng)校-考研-圖譜-下載-招聘  
分類
國家級省級浙江省各省雜志
科技核心北大核心CSCDCSCD擴展
工具
期刊知識寫作指導(dǎo) 論文投稿推薦期刊
期刊驗證論文檢測 錄用通知往期目錄
SCI
SCI指導(dǎo)影響因子
期刊點評基金動態(tài)
其它
經(jīng)濟教育計算機
建筑體育農(nóng)業(yè)
北京|天津|河北|山西|湖北|江蘇|安徽|山東|上海|浙江|江西|福建|湖南|寧夏|內(nèi)蒙古|河南
四川|重慶|貴州|云南|遼寧|吉林|廣東|廣西|海南|陜西|甘肅|新疆|青海|衛(wèi)生部直屬|黑龍江|兵團
您現(xiàn)在的位置: 醫(yī)學(xué)全在線 > 醫(yī)學(xué)論文 > SCI期刊 > 正文:Neuropeptides if:2.067
    

Neuropeptides


Neuropeptides
影響因子: 2.067
I S S N: 0143-4179 (印刷版) 1532-2785 (電子版) 0143-4179 (ISSNLinking)
出 版 社: Churchill Livingstone
出 版 地: Edinburgh ; New York
出版國家: Scotland
刊  期: 雙月刊
創(chuàng)刊時間: 1980
語  種: 英文
審稿周期: 12周,或約稿
中科院分區(qū): 3
投稿命中率: 較易
國外數(shù)據(jù)庫收錄: IM
中國收錄文章數(shù): 14
5年影響因子: 1.859
研究領(lǐng)域: 神經(jīng)病學(xué)、肽
官方鏈接: http://www.sciencedirect.com/science/journal/01434...
投稿須知: http://www.sciencedirect.com/science/journal/01434...

期刊介紹:

The aim of Neuropeptides is the rapid publication of original research and review articles, dealing with the structure, distribution, actions and functions of peptides in the central and peripheral nervous systems. The explosion of research activity in this field has led to the idenfication of numerous naturally occurring endogenous peptides which act as neurotransmitters, neuromodulators, or trophic factors, to mediate nervous system functions. Increasing numbers of non-peptide ligands of neuropeptide receptors have been developed, which act as agonists or antagonists in peptidergic systems. The journal provides a unique opportunity of integrating the many disciplines involved in all neuropeptide research. The journal publishes articles on all aspects of the neuropeptide field, with particular emphasis on gene regulation of peptide expression, peptide receptor subtypes, transgenic and knockout mice with mutations in genes for neuropeptides and peptide receptors, neuroanatomy, physiology, behaviour, neurotrophic factors, preclinical drug evaluation, clinical studies, and clinical trials. Original papers predominate. Manuscripts may be of any length, but must be complete studies; preliminary communications are not accepted. Review articles and hypothesis papers are welcomed, and will be evaluated in the same way as experimental papers. Authors intending to submit a review are advised to communicate their intentions to the Editors, to avoid possible duplication.
...
關(guān)于我們 - 聯(lián)系我們 -版權(quán)申明 -誠聘英才 - 網(wǎng)站地圖 - 網(wǎng)絡(luò)課程 - 幫助
醫(yī)學(xué)全在線 版權(quán)所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP備12017320號
百度大聯(lián)盟認(rèn)證綠色會員實名網(wǎng)站 360認(rèn)證可信網(wǎng)站 中網(wǎng)驗證